CRI Trial Logo

Advancing clinical discovery to bring promising new immunotherapy treatment options to cancer patients

An Essential Step Toward a Cure

Clinical trials are an essential step toward regulatory approval of new cancer treatments. Patients who volunteer for these studies not only gain access to cutting-edge immunotherapies and receive the best quality cancer care but also help to further the greater cause of finding immunotherapy-based cures for all cancer patients.

A child hugs his father

Driven by Data

CRI clinical trials are driven by the latest scientific data as well as the greatest opportunities for saving more lives, including finding more effective ways to help people with especially hard-to-treat, “orphan,” or rare and ultra-rare cancers.

CRI trials are built upon solid scientific rationale and are designed not only to help patients now but also to yield new insights that will benefit more patients with other cancers now and in the future.

Sharing Data to Stimulate New Ideas

Discoveries from CRI’s clinical work are shared across the entire international community of cancer immunologists. This sharing of data stimulates new ideas that lead to more progress. CRI convenes these leaders in immuno-oncology and facilitates dialogue to further the sharing of knowledge, fostering collaborations that otherwise would not happen.

The CRI Trials program includes the CRI Anna-Maria Kellen Clinical Accelerator – a first-of-its-kind venture philanthropy-backed clinical discovery strategy that supports multi-centered clinical trials testing novel immunotherapy combinations in hard-to-treat cancers – and our Clinical Innovator, which supports and coordinates investigator-initiated, single-site trials that leverage CRI’s global expert network to design and conduct innovative immunotherapy clinical trials.

Potential for a Universal Cure

Immunotherapy’s potential to treat all cancers effectively means that studies in one cancer type yield insights into treating other cancers. CRI identifies gaps in the global IO development pipeline where we and our partners can make the greatest impact.

CRI Trials include the following programs:

purple colorized cancer cells

Anna-Maria Kellen Clinical Accelerator

Centralized clinical studies that rely on CRI’s global think tank of clinical immuno-oncology experts to design and carry out early-stage clinical trials of novel immunotherapy combinations.

Two people engaged in conversation

Clinical Innovator

The Clinical Innovator supports transformational immunotherapy clinical trials proposed by academic researchers with the goal of advancing immunotherapies that provide the greatest impact on patient outcomes. CRI’s scientific advisors will prioritize trial concepts that address areas of unmet need in cancer research, and seek mechanistic insights into clinical response to achieve biomarker discovery.

Stylized graphic of a bar and line graph superimposed on one another

Immuno-Oncology Landscape

Regular analysis of immuno-oncology drug trials around the world, highlighting trends in the IO clinical drug development pipeline and guiding CRI and other clinical research programs seeking to make an impact both in increasing immunotherapy’s effectiveness overall as well as in underserved patient populations.

CRI Investments

In 2021, CRI decided to pursue early-stage equity investments in private companies that have direct affiliations with CRI and whose mission aligns with that of CRI. Annually, CRI surveys the CRI Network of scientists regarding near-term, early-stage investment opportunities. Criteria for investment include companies started by CRI scientists or where they hold senior positions. CRI conducts business, financial, legal, and scientific due diligence on identified opportunities. A key element of scientific due diligence is leveraging CRI’s Network to assist in evaluating the quality and validity of the technology.

Graphic of a map and map pin

Immuno-Oncology Clinical Trial Finder Service

Matches patients to immunotherapy clinical trials with the help of trial navigators, who work with patients and caregivers to find the most appropriate studies.

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.